CADL

Candel Therapeutics, Inc. [CADL] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

CADL Stock Summary

Top CADL Correlated Resources

CADL

Top 10 Correlated ETFs

CADL

Top 10 Correlated Stocks

CADL

In the News

CADL Financial details

Company Rating
-
Market Cap
195.45M
Income
-37M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
42
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-2.65
Forward P/E
-
PEG
-0.02
P/S
1306.06
P/B
1.76
P/C
-
P/FCF
-1.18
Quick Ratio
4.16
Current Ratio
4.37
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.27
EPS next Y
-
EPS next Q
-
EPS this Y
1217.91%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
37.15%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
31.03%
-
-
-
-
SMA20
-43.75%
SMA50
-35.71%
SMA100
13.03%
Inst Own
-
Inst Trans
-
ROA
-30%
ROE
1081%
ROC
-0.91%
Gross Margin
100%
Oper. Margin
-116690%
Profit Margin
-49200%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.66-11.4
52W High
-
52W Low
-
RSI
32.56
Rel Volume
0.07
Avg Volume
5.22M
Volume
385.35K
Perf Week
-11.57%
Perf Month
-45.4%
Perf Quarter
-18.3%
Perf Half Y
-22.77%
-
-
-
-
Beta
0.918
-
-
Volatility
0.24%, 1.67%
Prev Close
-1.31%
Price
4.51
Change
-2.17%

Something similar

Top by Market Cap
TL0.DE
GOOGL
BRK-A
M&M.NS
DHR-PB
Top Correlated ETFs
HYDR
CNCR
HDGB.L
HYGN.L
LABU
Top Correlated Stocks
VRNT
KOPN
3893.HK
0204.HK
ENVB
Similar Market Cap
ORN
ZPRU.DE
XDWM.L
DR0.DE
VIGL

Company Profile

Healthcare Biotechnology
  • Volume Average 5.22M
  • Market Capitalization 195.45M
  • Employee 42
  • CEO Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D.
  • Headquarters Needham,MA,US
  • IPO Date 2021-07-27
  • Website https://www.candeltx.com

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.